新京报贝壳财经讯 8月21日，康泰生物公告，2025年上半年营业收入13.92亿元，同比增长15.81%，归 属于上市公司股东的净利润3753.27万元，同比下降77.30%。基本每股收益0.03元／股，同比下降 80.00%。公司计划不派发现金红利，不送红股，不以公积金转增股本。 ...

资料显示，康泰生物专注于人用疫苗的研发、生产及销售，目前主要上市销售的产品有13 价肺炎球菌 多糖结合疫苗、无细胞百白破b型流感嗜血杆菌联合疫苗（四联苗）、冻干人用狂犬病疫苗（人二倍体 细胞）、23价肺炎球菌多糖疫苗、重组乙型肝炎疫苗(酿酒酵母)、b型流感嗜血杆菌结合疫苗、吸附无 细胞百白破联合疫苗、水痘减毒活疫苗等。 北京商报讯（记者 丁宁）8月21日晚间，康泰生物（300601）披露2025年半年度报告显示，2025年上半 年，公司实现营业收入13.92亿元，同比增长15.81%；归属净利润3753.27万元，同比下降77.3%。 ...

（文章来源：证券日报） 证券日报网讯 8月21日晚间，康泰生物发布公告称，公司第八届监事会第三次会议审议通过了《关于 2025年半年度报告及摘要的议案》。 ...

Core Viewpoint - 康泰生物 reported a significant increase in revenue and R&D investment, indicating strong growth potential in the vaccine sector and ongoing innovation in vaccine development [1][2] Group 1: Financial Performance - In the first half of 2025, the company achieved operating revenue of 1.392 billion yuan, a year-on-year increase of 15.81% [1] - In Q2, the company generated operating revenue of 747 million yuan, reflecting a quarter-on-quarter growth of 15.76% [1] - R&D investment reached 334 million yuan, up 41.52% year-on-year, accounting for 23.96% of the operating revenue [1] Group 2: Vaccine Development Initiatives - The company is focusing on global innovative vaccine products, particularly developing a vaccine for Klebsiella pneumoniae, which is known for its antibiotic resistance and pathogenicity [1] - 康泰生物 established a joint venture with AstraZeneca to develop innovative vaccines for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), with no similar products currently available globally [1] - The company has nearly 30 projects under development, with 3 in the production registration application stage and 15 in clinical trial stages [2] Group 3: Progress on Research Projects - The 60μg recombinant hepatitis B vaccine aimed at preventing recurrence in functional cure populations has received Pre-IND feedback from CDE and is in the process of completing clinical application documentation [2] - The five-in-one vaccine (DTPaHibIPV) has obtained preliminary data from Phase I clinical trials and is currently in discussions with CDE regarding Phase III clinical matters [2] - The 20-valent pneumococcal polysaccharide conjugate vaccine is in Phase I and II clinical trials, while the 24-valent pneumococcal polysaccharide conjugate vaccine has completed preclinical research and received Pre-IND feedback from CDE [2]

智通财经APP讯，康泰生物(300601.SZ)发布2025年半年度报告，该公司营业收入为13.92亿元，同比增 长15.81%。归属于上市公司股东的净利润为3753.27万元，同比减少77.30%。归属于上市公司股东的扣 除非经常性损益的净利润为1845.86万元，同比减少84.85%。基本每股收益为0.03元。 （原标题：康泰生物(300601.SZ)发布上半年业绩，归母净利润3753.27万元，下降77.30%） ...

（记者 王晓波） 每经AI快讯，康泰生物（SZ 300601，收盘价：18.56元）8月21日晚间发布公告称，2025年半年度，公 司计提信用减值准备、资产减值准备金额共计约1.21亿元，计入公司2025年半年度损益，减少公司2025 年半年度归属于母公司股东的净利润及所有者权益约1.03亿元。本次资产减值对公司持续经营能力不会 产生重大影响。本次计提资产减值准备金额未经审计。 2024年1至12月份，康泰生物的营业收入构成为：生物制品占比98.31%，其他业务收入占比1.69%。 截至发稿，康泰生物市值为207亿元。 每经头条（nbdtoutiao）——核心产品净值仅剩7毛钱，昔日"公募一哥"任泽松怎么了？牛市踏空真相曝 光 ...

Core Insights - 康泰生物 reported a revenue of 1.392 billion yuan for the first half of 2025, representing a year-on-year growth of 15.81% [1] - The company is focusing on transforming into a global innovative biopharmaceutical enterprise while addressing key public health challenges [2] Financial Performance - The company achieved a net cash flow from operating activities of 75.597 million yuan, an increase of 31.42% year-on-year [1][4] - Cumulative net cash flow from operations for the years 2022 to 2024 is approximately 2.2 billion yuan, indicating a strong financial foundation for sustainable development [4] Research and Development - R&D investment reached 334 million yuan in the first half of 2025, a year-on-year increase of 41.52%, accounting for 23.96% of the revenue [2] - The company has nearly 30 projects in the pipeline, with 3 in the production registration phase and 15 in clinical trials, covering key global vaccine products [3] Product Development - The company is developing a vaccine for Klebsiella pneumoniae, a critical pathogen listed by WHO, targeting high-risk groups [2] - Recent progress includes feedback on a hepatitis B vaccine and initial data from a combined vaccine for pertussis and polio [3] International Expansion - 康泰生物 is expanding its international market presence, focusing on emerging markets along the Belt and Road Initiative, with partnerships in over 20 countries [5] - The company has achieved significant milestones, including GMP certification for its pneumococcal vaccine in Turkey and product registration in Indonesia [5] Future Outlook - The company aims to enhance its commercialization capabilities for existing and future innovative vaccine products through extensive overseas collaborations [6]

Group 1 - The core viewpoint of the article highlights that Kangtai Biological (300601) reported a revenue of 1.392 billion yuan for the first half of 2025, representing a year-on-year growth of 15.81% [1] - The company's net profit attributable to shareholders decreased to 37.53 million yuan, reflecting a significant decline of 77.3% compared to the previous year [1] - Basic earnings per share for the company stood at 0.03 yuan [1] Group 2 - The company has been actively engaged in the research and development of globally innovative products, including a vaccine for Klebsiella pneumoniae [1]

格隆汇8月21日丨康泰生物(300601.SZ)公布2025年半年度报告，上半年公司实现营业收入13.92亿元，同 比增长15.81%；归属于上市公司股东的净利润3753.27万元，同比下降77.30%；归属于上市公司股东的 扣除非经常性损益的净利润1845.86万元，同比下降84.85%；基本每股收益0.03元。 ...

康泰生物公告，2025年上半年营业收入13.92亿元，同比增长15.81%。归属于上市公司股东的净利润 3753.27万元，同比下降77.30%。基本每股收益0.03元／股，同比下降80.00%。公司计划不派发现金红 利，不送红股，不以公积金转增股本。 ...